FIG A6.

Treatment status of survivors at 5 years. ^aMedian (range) nivolumab treatment duration: 36.9 (1.8-76.2 +) months. ^bThe other 3 patients progressed (1.8, 4.5, and 44.2 months, respectively) after discontinuing nivolumab treatment. ^cAfter nivolumab treatment. ^dInformation on subsequent therapy was not available as of database lock. ^eNivolumab treatment durations for individual patients: 8.8, 21.7, 36.6, 43.3, and 43.5 months. ^fMedian (range) nivolumab treatment duration: 68.4 (62.9-76.2 +) months. ^gIncludes two patients treated with nivolumab as first subsequent therapy. ^hBecause of the receipt of subsequent therapy. AE, adverse event; TRAEs, treatment-related adverse events.